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What does this paper add to the literature? 
This is the first study to show that performing prehabilitation in patients with rectal cancer 
undergoing neo-adjuvant chemoradiotherapy is feasible, safe and well tolerated by patients. 
With no reported interruption to each participant’s planned clinical management, these 
findings support progression to a large powered multi-centred trial.  
Abstract  
Background. Rectal cancer patients undergoing NACRT (neo-adjuvant chemoradiotherapy) 
experience physical deterioration and reductions in their quality of life. This feasibility study 
assessed pre-habilitation (a walking intervention) before, during and after NACRT to inform a 
definitive multi-centred RCT (Rex trial) . 
 
Methods. Patients planned for NACRT followed by potentially curative surgery were 
approached (August 2014 - March 2016) (www.isrctn.com; 62859294).  Prior to NACRT, baseline 
physical and psycho-social data were recorded using validated tools..  Participants were 
randomised to either the intervention (exercise counselling session followed by 13-17 weeks 
telephone-guided walking programme) or control group (standard care).  Follow-up testing 
was undertaken 1-2 weeks before surgery. 
 
Results. Of 296 screened patients, 78(26%) were eligible and 48 (61%) were recruited. n (65%) 
were  male with a mean age 65.9 ± years (SEM ? rather than range? range 33.7-82.6).  Mean 
intervention duration was 14 weeks with 75% adherence.  n(83%) completed follow-up testing.  
Both groups recorded reductions in daily walking but the reduction was less in the Intervention 
group.  Participants reported high satisfaction and fidelity to trial procedures. 
  
Conclusion. This study demonstrates that prehabilitation is feasible in rectal cancer patients 
undergoing NACRT. Good recruitment, adherence, retention and patient satisfaction rates 
support the development of a fully powered trial.  The effects of the intervention on physical 
outcomes were promising.   
 
Introduction 
Earlier diagnosis and advances in surgery and chemo-radiotherapy are improving long-term 
survival for rectal cancer 1. Long-course neo-adjuvant chemoradiotherapy (NACRT) can down-
stage locally advanced rectal cancer optimising the chance of an R0 resection or in the event of 
a complete response, removing the immediate need for major pelvic surgery 2,3,4,5.   However,  
5-6 weeks of NACRT can be challenging.   About 22% of patients experience severe acute side 
effects such as haematological toxicity, sepsis, enteritis, radiological dermatitis and 
cardiotoxicity 6. This morbidity can adversely affect patients physically, mentally and socially 
7,8,9. Whilst many patients have low levels of physical fitness at diagnosis,  NACRT has the 
potential to further weaken patients 10.  
  
Patients approaching major surgery with poorer physical fitness (aerobic capacity, muscular 
strength, endurance, flexibility and body composition) are at greater risk of post-operative 
morbidity and mortality 11,12,13,14,15.  Prehabilitation, an intervention to enhance the functional 
capacity of the individual to withstand a stressful event, has become an evolving area of 
interest.   Studies have been published which have assessed feasibility and influence on post-
operative outcomes  vary in their methodology and patient population16,17,18.   A systematic 
review of major abdominal surgery concluded that prehabilitation decreased the incidence of 
post-operative major complications19.  
 
For rectal cancer patients, there is a minimum 2 months from completion of NACRT to 
definitive surgery and this provides a window for prehabilitation, which is unavailable to 
patients going straight to surgery given the current local target of 31 days 20.  
 
One non-randomised study of 39 patients reported a reduction in physical fitness [using 
cardiopulmonary exercise testing (CPET)] after long-course NACRT.  Only those patients who 
received three supervised aerobic sessions per week for six weeks returned to baseline fitness 
levels at a third CPET study 17.  
A Canadian study recruited 18 patients to undergo prehabilitation during and afer NACRT 21.  
This consisted of a supervised aerobic exercise programme (three sessions per weeks during 
NACRT) followed by an unsupervised programme (target of 150 minutes plus per week for 6-8 
weeks after NACRT).  There were no serious adverse events in the 56% patients who completed 
the programme and the authors concluded that the next step should be a feasibility study.  
 
 
  The aim of our study was to assess the feasibility of performing a physical activity intervention 
prior to, during and after NACRT in patients with rectal cancer. The primary aim was to assess 
feasibility of delivering such an intervention with indicative outcomes also recorded to inform 
design of a definitive randomised controlled trial (RCT).  
 
 
Methods 
 
The study ran from August 2014 to March 2016 (20 months).  Patients (age>18 years)  
presenting with a new diagnosis of rectal cancer in one NHS trust (Greater Glasgow and Clyde, 
GGC) between August 2014 and March 2015 were considered eligible for the REx Trial if they 
satisfied the following: a histological confirmed adenocarcinoma,  an MRI which suggested 
either threatened margins and/or low rectal tumour, a CT thorax/abdomen/pelvis which 
excluded metastatic disease and finally, MDT recommendation for long-course neo-adjuvant 
chemo-radiotherapy (NACRT) followed by potentially curative surgery. Patients were excluded 
for the following : metastatic disease, reduced mobility  sufficient to prevented any walking 
intervention,  already achieving recommended government guidelines for physical activity per 
week (using The Scottish Physical Activity Screening Questionnaire)22 or they had any physical, 
mental or psychological impairment that prevented signed informed consent.  
 
The trial was approved by the West of Scotland Research Ethics Service (14/WS/0079) and 
registered with ISRCTN (www.isrctn.com; 62859294; 17th March 2014). The trial was reported 
using the CONSORT 2010 Guidelines 23. This study was funded by the Chief Scientist Office 
(CZH/4/986). www.cso.scot.nhs.uk 
 
Trial Design. This was a two-arm randomised controlled feasibility study (RCT). Potentially 
eligible patients were screened by the trial team and then approached by the patient’s 
colorectal cancer nurse specialist at the time of one of their surgical or oncological 
consultations. Any potential recruit was telephoned and if still interested scheduled for 
consent and baseline testing. Informed written consent was taken by participating colorectal 
surgeons according to the standards of Good Clinical Practice (ref). 
 
Primary Outcomes. The primary outcomes were feasibility and acceptability of the research 
procedures, as assessed by eligibility and recruitment rates (including reasons for non-
participation), participant acceptability of randomisation, data collection and physical 
intervention and rates of retention and adherence to the physical activity intervention. 
Acceptability of randomisation was estimated from the percentage of participants attending 
baseline measurements who gave informed consent to take part in the feasibility trial. The 
number of telephone calls planned and subsequently received by each participant in the 
intervention group during the physical activity intervention measured adherence to the 
intervention. Trial satisfaction was assessed by asking each participant how much they were in 
agreement with the following 4 questions using a Likert scale from 1 (not at all in agreement) 
to 5 (very much in agreement): how satisfied were you with the REx Trial,  how convenient did 
you find coming up to the hospital for trial appointments, how easy did you find the pedometer 
to use (intervention group only) and how likely would you be to recommend the REx trial to 
other people with rectal cancer? 
 
At the weekly telephone call to each participant in the intervention group, the research 
assistant was asked to grade the fidelity of the intervention using a Likert score (1- poor to 5 – 
high).  Any protocol deviations were recorded. 
 
Secondary Outcomes. The primary efficacy outcome was median step count per day. Other 
secondary outcomes included physical, psychological and peri-operative variables. All 
outcomes were assessed at baseline testing pre-intervention (Baseline Test 1 prior to 
undergoing NACRT) and repeated post-intervention (1-2 weeks pre-surgery, Test 2) with peri-
operative variables collected within the first few weeks after surgery [Figure 1].   
 
 
In addition to demographic and clinico-pathological characteristics the following physical 
measurements were taken: weight, height, hip and waist circumference, sit-to-stand test and 6 
minute walking test (6MWT). Waist circumference was measured with a measuring tape, with 
participants in the standing position and the tape positioned midway between the lateral lower 
rib margin and the iliac crest 24. If these landmarks could not be identified, the measurement 
was taken at the level of the umbilicus. Hip measurement was taken around the widest portion 
of the buttocks. Both measurements were taken twice. Weight and height allowed calculation 
of Body Mass Index (BMI): weight (kg)/[height (m)2]. Sit-to-stand test was administered over 
30 seconds, during which each participant crossed their arms and moved from sitting to full 
standing position (body straight). This was repeated as many times as possible during the 
timeframe to allow assessment of functional lower extremity strength that has been validated 
in many groups, especially older adults 25. The 6MWT is an objective measurement of functional 
exercise capacity that in addition to being safe in a variety of populations, has shown good 
correlation with 12 minute walk test and cycle ergometer and treadmill exercise tests 26,27. A flat, 
indoor surface was selected with markers placed 12.5m apart.  Participants were then 
requested to walk as far as they could in the 6 minutes with the final distance (m) being 
recorded.  
 
At the end of the baseline testing each participant was instructed on how to use the 
accelerometer to record data for 3-5 days. The activPAL (activPAL3, PAL Technologies, Glasgow, 
UK) is a small (53 x 35 x 7mm) lightweight (15g) triaxial accelerometer, secured on the anterior 
thigh with an adhesive dressing, allowed anonymous data collection.  Data were uploaded 
using the activPAL software recorded the daily   sedentary time, active time and average steps 
walked.. Mean daily step counts were categorised as follows: sedentary (<5000steps/day); 
mildly active (5000-6999); moderately active (7000- 10999) and very active (≥11000 steps) 28. 
Each participant repeated this after Test 2.  
 
Questionnaires. Each participant completed the following at pre-NACRT and post-NACRT 
testing: Becks Depression Inventory (BDI-II), FACT-C, PANAS, EORTC-QLQ CR29 and C30.  The 
existence and severity of symptoms of depression was measured using BDI-II 29. A total of 21 
items are summed to give a single point score: 0-13 normal or minimal depression; 14-19 mild; 
20-28 moderate and 29-63 severe. Colorectal cancer specific quality of life was measured using 
the Functional Assessment of Cancer Therapy – Colorectal (FACT-C). This includes 27 items from 
the FACT-General (FACT-G) and adds in 11 items specific to colorectal cancer, with a higher 
score indicating a better quality of life and a change of at least 2 being stated as clinically 
relevant 30. The Positive and Negative Affect Schedule (PANAS) is a 20-item self-reported 
measure of two scales, one to measure positive affect (where higher scores represent higher 
levels of positive affect) and the other, negative affect (where lower levels represent lower 
levels of negative affect) 32. EORTC QLQ-C30 is the widely used and validated quality of life 
questionnaire for all cancer patients by the European Organisation for Research and Treatment 
of Cancer. It comprises nine multi-item scales and six single item scales. EORTC QLQ-C29 
specifically assesses quality of life in colorectal cancer patients and was administered alongside 
the C-30 32. 
 
Randomisation. Participants were randomised 1:1 to either the physical intervention or control 
group (standard care) using block size 4 and no stratification. Randomisation was performed 
using an interactive voice response (IVR) telephone system provided by the Robertson Centre 
for Biostatistics. After each participant had completed pre-NACRT testing, the research 
assistant received the group allocation via the IVR system and provided it to the participant.  
The testers were blinded to the group allocation throughout as were their surgeons, nurse 
specialists and hospital staff involved in their care. 
 
 
Physical Activity Intervention. Participants randomized to the intervention group had an initial 
face-to-face consultation with the study co-ordinator who had been trained in the application 
of two behavioural theoretical frameworks:  self-regulatory theory (providing techniques to 
improve impulse control allowing walking targets to be reached) and the health action process 
approach (replacing behaviours that compromise health with those that enhance health) 33,34. 
 
The walking programme started prior to NACRT and was of minimum 13 weeks duration: 5 
weeks of NACRT followed by minimal time interval of 8 weeks prior to surgery determined by 
individual surgeon’s usual practice. The programme was based on targeted stepping counts: 
the first 8 weeks consisted of graduated goals calculated from the baseline stepping count 
(identified from the pre-NACRT accelerometer result) with that behaviour then maintained or 
increased over the remaining weeks up to surgery. Each participant was given a weekly walking 
diary (targets and motivational material included) and the use of the pedometer explained. 
Participants then received follow-up telephone calls (weeks 1,3,5,7,9,12,16) where new stepping 
targets were set, motivational techniques applied and any issues discussed. All participants 
were asked to engage a support person (e.g. spouse) to assist in their adherence with the 
programme.  
 
The target was for the participants to increase their average daily step count by 3000 
accumulated above their baseline value which is a protocol that has been used successfully by 
this research team before and other researchers 28,35,36,37,38. This is based on the assumption 
that an adult walking at a moderate pace produces 100 steps/ minute. Therefore an increase of 
3000 steps in one day is equal to 30 minutes extra activity that if performed on five days of the 
week would correspond to approximately 150 minutes of moderate physical activity over the 
course of the week which is the recommended physical activity level for adults in Scotland 22.  
 
 
Below is an example: 
Weeks 1-2: extra 1500 steps on at least 3 days a week. 
Weeks 3-4: extra 1500 steps on at least 5 days a week.  
Weeks 5-6: extra 3000 steps on at least 3 days a week.  
Weeks 7-8: extra 3000 steps on at least 5 days a week.  
Weeks 9-17: maintenance of weeks 7-8 or individually increased. 
 
Control Group. The control group received standard care with no contact from the trial team 
except at the two test sessions. When informed of their allocation to the control group, they 
were told to maintain their normal level of physical activity. They were offered a voluntary 
exercise counselling session and information pack from the trial team after their surgery and 
on completion of the trial. 
 
Neo-Adjuvant Chemoradiotherapy (NACRT). Radiotherapy dose was standardised at 4500 cGY 
in 25 fractions on weekdays only accompanied by oral Capecitabine 900mg/ m2 bd on the same 
days or 5FU 350 mg/m2 iv on weeks 1 and 5. 
 
Peri-operative Outcome Variables. For each participant that underwent surgery the following 
were recorded: length of hospital stay; surgery type; number of post-operative complications 39. 
In addition, pathology of the resected specimen was recorded.  
 
Sample Size. This was a phase 1 feasibility study to test practical aspects of the study design 
and to help inform the calculation of effect sizes for a subsequent definitive fully powered RCT. 
From The West of Scotland Colorectal Cancer Managed Clinical Network 2013 - 2014 data, 
approximately one hundred patients per year were deemed eligible for inclusion in this study.  
We estimated that we could recruit 80 patients during the planned 18-month trial recruitment 
period (40 intervention and 40 control), and this would provide sufficient data to determine 
feasibility.  
 
Statistical Analysis. The main aim was to assess feasibility of intervention delivery to inform 
design of a main trial, thus the indicative outcomes are underpowered for statistical 
interpretation. Descriptive tables to summarise the feasibility measures by each group were 
performed, with means and standard deviations or medians and interquartile ranges (IQR) 
calculated for continuous variables, depending on whether or not they were normally 
distributed; and counts and percentages for categorical variables.  Wilcoxon tests were used to 
compare satisfaction scores between study groups.   
 
The most relevant physical outcome (measured average daily step count) was compared 
between groups using a linear regression model fitted to change from baseline, adjusting for 
the number of steps per day at baseline, age and gender, and presented as a mean estimate of 
the group difference with a corresponding 95% confidence interval. Study group comparisons 
of change from baseline in other physical and psychological outcome measures were carried 
out using two-sample t-tests and within-group comparisons for all measures of within-patient 
change from baseline to follow-up using paired t-tests, and both were presented as mean 
estimates and corresponding 95% confidence intervals. The EORTC-C29 embarrassment 
measure was compared from baseline to follow-up within groups using multinomial tests, and 
change from baseline between groups was assessed using a Fisher’s exact test.  
 
All statistical analysis was undertaken using R for Windows version 3.4.1 or the SAS application 
software (version 9.3, SAS Institute Inc., Cary, NC, USA). 
Results 
Feasibility. 
During the trial’s timeframe a total of 296 patients were diagnosed with rectal cancer.  78 
patients were put forward by their MDT for NACRT (26%) [Figure 1, Consort Diagram]. 
Screening showed that all 78 patients were eligible for the trial and were approached, with 48 
patients attending for baseline testing and consent (recruitment rate 62%). The main reasons 
given for not participating were: ‘too much going-on’ and ‘overwhelmed by diagnosis’. No 
patients were excluded for achieving the recommended government guidelines for physical 
activity per week. 
 
All participants completed baseline testing and randomisation with 24 participants randomised 
to the intervention group [Table 1]. Median walking intervention duration of 14 weeks (IQR 13-
17) was completed with 80% of planned telephone calls to the intervention group being 
achieved and 75% completing the intervention [Table 1].   
 
Overall, a total of 8 participants did not complete the study: 6 from the intervention group and 
2 controls (retention rate 83%). Two of the intervention group withdrew prior to starting the 
intervention and of the remaining 6 drop-outs, 4 were for medical reasons {Figure 1]. There 
were no serious adverse events reported and no treatment pathways were modified as a 
consequence of trial participation. 
 
At the end of the trial, participants from both groups reported high levels of satisfaction with 
the trial and would recommend prehabilitation  to other patients [Table 1]. Intervention fidelity 
assessments found an overall mean score of 4.0 (range 1-5) for the telephone-guided 
intervention. Deviations from the protocol included several attempts by the research assistant 
to contact participants on their telephone and modifying the weekly target step count 
depending on the participant’s weekly clinical status. 
 Baseline Participant Characteristics. 
Participants had a mean age of 65.9 years (range 33.7-82.6) and were: predominately male 
(65%) and of white ethnicity (96%) and all were educated to at least completion of secondary 
education. 38% of participants were from the two most deprived socioeconomic groups. Co-
morbidities were present in 57%, with hypertension (present in 59% of those with co-
morbidities) and arthritis (30%) most commonly recorded [Table 2].  
 
Most (60%) participants currently or had previously smoked, 88% reported current alcohol 
consumption, 71% were overweight (BMI≥25) with 19% obese (≥30). The majority of participants 
(90%) stated they could complete a flight of stairs without stopping; however, on average were 
only active for 1.6 hours a day (6.6% of their week).  The mean number of steps per day of all 
participants was 7392 (range 1151 to 17422) with 54% classified as sedentary or only slightly 
active [Table 3]. In relation to psychological testing, participants did not report being 
depressed [BDI mean score 7.2 (6.6)] and had a reasonable quality of life although fatigue and 
embarrassment were commonly reported [Table 3].  
  
Follow-up Testing. 
Results from follow-up testing are displayed in Table 4. For the primary efficacy outcome 
(mean of the median daily step count), both groups recorded a reduction in step count: the 
intervention group dropped by a mean of 1105 steps (15% reduction from baseline), whilst the 
control group reported a greater drop of 1853 steps (24% reduction from baseline) [Figure 2]. 
This difference between groups in change from baseline of 785 [95% CI -1194,2765] was not 
significant (adjusted for baseline median daily step count, age and gender).  
 
A higher percentage of the intervention group achieved step count improvements at 12 weeks 
(23.5 versus 15.8%). The intervention group also documented a non-significant mean increase of 
13.7m in their 6MWT scores, while the control group showed a mean 54.8m reduction, which 
resulted in a non-significant between-group difference of 68.5m (95% CI [-27.2,164.2]).  
There were no statistically significant changes within and between groups in relation to any of 
the psychological questionnaires. 
  
 Peri-operative Outcome Variables. 
Table 5 describes the clinico-pathological factors in all participants finding the majority 
successfully completed NACRT (98%). Most participants (36 out of 40) underwent surgery with 
33 being of curative intent, 2 local excision due to poor fitness and 1 had a defunctioning stoma 
performed. Of the 4 patients that did not undergo surgery, 3 had progressive disease on their 
post-NACRT imaging with the other participant having a complete response to NACRT on 
follow-up imaging.  
 
The majority of surgery was performed electively (97%), by an open approach (72%) with a 
permanent end-colostomy formed in 61%. All grades of post-operative complications were 
recorded in 67% of cases with T3 N0 being the most commonly recorded pathological TNM 
staging.  The tumour was completely resected (R0) in 86% of surgical procedures. 
 
Discussion 
This is the first RCT to assess the feasibility of performing a walking intervention 
(prehabilitation) in patients with rectal cancer undergoing NACRT and with good recruitment, 
good retention and high participant satisfaction with trial procedures, all without compromise 
to the planned treatment pathway, these results support proceeding to a future definitive 
higher powered multi-centred RCT.  
 
The demographics of the participants shows that performing a walking intervention is feasible 
in groups that can be considered challenging in both recruitment and adherence; older adults 
(40% were over 70), those with high levels of socioeconomic deprivation (38%) and in patients 
with co-morbidities, including potentially activity limiting conditions, such as arthritis. 
Furthermore many participants reported smoking, alcohol consumption and being overweight, 
in addition to high levels of sedentary behaviour. Many of these factors either by themselves or 
in combination are traditionally associated with a patient potentially being labelled as ‘high risk’ 
for treatment morbidity and mortality, a statement that is supported by the reported 
complication rate of 67% in this study. Indeed, previous work has found that such patients 
account for 85% of peri-operative complications making them a key area to target.  Despite this 
many prehabilitation protocols have excluded such patients 40. One recently published RCT 
supports our findings by recruiting only high-risk patients going straight to major abdominal 
surgery.  This study  defined “high-risk” as age > 70 years and/ or American Society of 
Anaesthesiologists score III/ IV 41. With a mean intervention time of 6 weeks to perform a 
multimodal prehabilitation programme (lifestyle counseling, nutrition assessment, iron therapy 
as appropriate accompanied by a physical activity programme), the authors reported that 54 
out of 73 completed the intervention (73%) without any serious adverse events. In addition, 
these authors found a significant reduction in post-operative complications in the 
prehabilitation group compared to the usual care controls (31% versus 62%; p=0.001).  
 
These results suggest that not only is prehabilitation feasible in high-risk patients, but that their 
risk of complications can be modified.  
 
The reduction in daily step counts of the participants confirms the previously reported negative 
effect that NACRT has on physical function in patients with rectal cancer 17. Instituting a   
walking intervention is a proactive approach that may offset this decline and this is supported 
by the intervention group step count results from this study.  However, a definitive trial needs 
be powered for daily step count as its primary aim.   Consideration must be given to delivering 
the optimal intervention that leads to the majority of participants in the intervention group 
achieving improved step counts.  Individualized walking programmes have achieved success in 
older adults  and over a shorter time frame 35,36,37,42.  Previous focus group work has mentioned 
the role of an  exercise counselor and how increased contact time (either by phone or face to 
face) could increase motivation and adherence to step targets. The role of motivational 
feedback also needs to be established as does the exact timing of treatment and testing after 
completion of NACRT.   Specific strategies for dealing with fatigue need to be identified as this 
was a commonly reported barrier to patients undergoing prehabilitation.  
 Health professionals need to be educated as to the benefits of prehabilitation as a part of their 
routine management. This need for both health care professional and patient education is 
suggested by the two main refusal reasons for participation in this study: ‘too much going-on’ 
and ‘overwhelmed by diagnosis’.  
 
Colorectal nurse specialists performed the initial approach and, at the outset, many were 
unaware or uncertain about the definition of prehabilitation and its potential role whilst 
undergoing treatment and its influence on long-term cancer related outcomes 43,44,45. With 
education through face-to-face meetings and invited presentations at colorectal nurse 
meetings, in addition to their own patients’ feedback, a culture change occurred. With nurse 
specialists documented as a preferred source of information for cancer patients, consideration 
to education for these specialists should be integrated in the future trial protocol 46.  
 
Limitations. 
The authors acknowledge limitations of this predominately single-centred feasibility study. 
Selection bias cannot be excluded because motivated patients are  more likely to participate in 
prehabilitation .  Data about the walking intervention may have  been biased as it was self-
reported: future studies should consider using more objective measures to avoid this. The 
power of this feasibility study was reduced because we could not recruit the target of 80 
patients.  This was because the total number of rectal cancer patients suitable for NACRT had 
declined slightly from the previous year.  We think that  this could be overcome with a large 
multi-centred trial. Recrutment for prehabilitation may become more important as more early 
rectal cancers (stage 1 and 2) are considered for NACRT and a potential “watch and wait” 
policy for ‘complete responders’ (no residual disease on post-NACRT imaging). 
 
 
 
 
Conclusion. 
This is the first RCT to assess the feasibility of performing a walking intervention 
(prehabilitation) in rectal cancer patients undergoing NACRT followed by potentially curative 
surgery. Even though rectal cancer treatment is multimodal and was evolving during the study 
period, prehabilitation was found to be feasible in a predominately inactive, co-morbid, older 
adult population. With good recruitment, adherence and retention rates and the possibility of 
reducing the physical deterioration of NACRT, these results support the development of a fully 
powered trial to investigate the influence of prehabilitation on optimising physical function and 
patient related outcomes. 
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Table 1: Feasibility outcomes in the REx Trial: Subject Participation and satisfaction scores. 
 
Participation 
 
    
All Participants 
 
    
 
Recruited 
   
48 
 
Screening visit and Test 1 completed   48 (100%)  
Randomisation visit completed   48 (100%)  
Test 2 completed   40 (83%)  
     
Intervention group (n=24) 
 
    
 
Diary and walking intervention completed  
   
 
18 (75%) 
 
 
Number of completed intervention weeks 
  
Median (IQR) 
 
14 (13-17) 
 
  Range 0-17  
     
Total number of Telephone calls  Planned 116  
  Performed 93 (80%)  
     
No of telephone calls per participant  Median (IWR) 5(4-6)  
  Range 1-6  
 
 
    
Satisfaction Scores 
 
ALL Intervention 
 
Control  
 Median (IQR) 
 
Median (IQR) 
 
Median (IQR) 
 
P value 
How satisfied were you with The REx Trial 
 
5.0 
(4.0-5.0) 
5.0 
(5.0-5.0) 
4.5 
(4.0-5.0) 
0.019 
How convenient did you find coming up to 
the hospital for trial appointments? 
 
4.0 
(4.0–5.0) 
4.0 
(4.0-5.0) 
4.0 
(3.0-5.0) 
0.120 
For the intervention group: How easy did 
you find the pedometer to use? 
 
5.0 
(5.0-5.0) 
5.0 
(5.0-5.0) 
  
How likely would you be to recommend 
The REx Trial to other people with a 
diagnosis of rectal cancer 
5.0 
(4.0–5.0) 
5.0 
(4.0–5.0) 
5 
(4.0.5.0) 
0.230 
*Scored using Likert scale from 1 (not at all in agreement) to 5 (very much in agreement). 
Table 2: Comparison of Demographics, Co-morbidities and Lifestyle Factors of Participants with 
Rectal Cancer recruited to the REx Trial: Intervention group versus Control group. 
 
 
 
Statistic 
All 
(N = 48) 
Intervention 
(N = 24) 
Control 
(N = 24) 
Age (years) Nobs (Nmiss) 46 (2) 24 (0) 22 (2) 
 Mean (SD) 65.9 (10.5) 65.2 (11.4) 66.5 (9.6) 
Sex Nobs (Nmiss) 48 (0) 24 (0) 24 (0) 
   Male N (%) 31 (65%) 18 (75%) 13 (54%) 
   Female N (%) 17 (35%) 6 (25%) 11 (46%) 
Ethnicity Nobs (Nmiss) 48 (0) 24 (0) 24 (0) 
   White N (%) 46 (96%) 22 (92%) 24 (100%) 
   Asian, Asian Scottish or Asian British N (%) 1 (2%) 1 (4%) 0 (0%) 
   African N (%) 1 (2%) 1 (4%) 0 (0%) 
Education level Nobs (Nmiss) 44 (4) 20 (4) 24 (0) 
   Secondary Education N (%) 21 (48%) 11 (55%) 10 (42%) 
   Higher/Further Education N (%) 19 (43%) 8 (40%) 11 (46%) 
   Other N (%) 4 (9%) 1 (5%) 3 (12%) 
SIMD Nobs (Nmiss) 47 (1) 23 (1) 24 (0) 
   1 (most deprived) N (%) 9 (19%) 4 (17%) 5 (21%) 
   2 N (%) 9 (19%) 6 (26%) 3 (12%) 
   3 N (%) 13 (28%) 7 (30%) 6 (25%) 
   4 N (%) 10 (21%) 4 (17%) 6 (25%) 
   5 (least deprived) N (%) 6 (13%) 2 (9%) 4 (17%) 
ASA Nobs (Nmiss) 47 (1) 23 (1) 24 (0) 
   1 N (%) 0 (0%) 0 (0%) 0 (0%) 
   2 N (%) 32 (68%) 18 (78%) 14 (58%) 
   3 N (%) 15 (32%) 5 (22%) 10 (42%) 
   4 N (%) 0 (0%) 0 (0%) 0 (0%) 
   5 N (%) 0 (0%) 0 (0%) 0 (0%) 
Co-morbidities Nobs (Nmiss) 47 (1) 24 (0) 23 (1) 
   No N (%) 20 (43%) 12 (50%) 8 (35%) 
   Yes N (%) 27 (57%) 12 (50%) 15 (65%) 
Diabetes Nobs (Nmiss) 27 (0) 12 (0) 15 (0) 
   No N (%) 25 (93%) 10 (83%) 15 (100%) 
   Yes N (%) 2 (7%) 2 (17%) 0 (0%) 
BMI Nobs (Nmiss) 48 (0) 24 (0) 24 (0) 
   <20 N (%) 2 (4%) 2 (8%) 0 (0%) 
   20-24.9 N (%) 12 (25%) 8 (33%) 4 (17%) 
   25-29.9 N (%) 25 (52%) 12 (50%) 13 (54%) 
   30-34.9 N (%) 8 (17%) 2 (8%) 6 (25%) 
   35+ N (%) 1 (2%) 0 (0%) 1 (4%) 
Hypertension Nobs (Nmiss) 27 (0) 12 (0) 15 (0) 
   No N (%) 11 (41%) 5 (42%) 6 (40%) 
   Yes N (%) 16 (59%) 7 (58%) 9 (60%) 
COPD Nobs (Nmiss) 27 (0) 12 (0) 15 (0) 
   No N (%) 25 (93%) 11 (92%) 14 (93%) 
   Yes N (%) 2 (7%) 1 (8%) 1 (7%) 
MI Nobs (Nmiss) 27 (0) 12 (0) 15 (0) 
   No N (%) 24 (89%) 10 (83%) 14 (93%) 
   Yes N (%) 3 (11%) 2 (17%) 1 (7%) 
CVA Nobs (Nmiss) 27 (0) 12 (0) 15 (0) 
   No N (%) 26 (96%) 11 (92%) 15 (100%) 
   Yes N (%) 1 (4%) 1 (8%) 0 (0%) 
Arthritis Nobs (Nmiss) 27 (0) 12 (0) 15 (0) 
   No N (%) 19 (70%) 9 (75%) 10 (67%) 
   Yes N (%) 8 (30%) 3 (25%) 5 (33%) 
Other co-morbidities Nobs (Nmiss) 27 (0) 12 (0) 15 (0) 
   No N (%) 22 (81%) 10 (83%) 12 (80%) 
   Yes N (%) 5 (19%) 2 (17%) 3 (20%) 
Weight (kg) Nobs (Nmiss) 48 (0) 24 (0) 24 (0) 
 Mean (SD) 76.2 (11.4) 75.4 (13.4) 77.0 (9.1) 
Smoking Nobs (Nmiss) 48 (0) 24 (0) 24 (0) 
   Current N (%) 7 (15%) 4 (17%) 3 (12%) 
   Ex (<12 months) N (%) 10 (21%) 7 (29%) 3 (12%) 
   Ex (>=12 months) N (%) 12 (25%) 4 (17%) 8 (33%) 
   Never smoked N (%) 19 (40%) 9 (38%) 10 (42%) 
Alcohol consumption Nobs (Nmiss) 48 (0) 24 (0) 24 (0) 
   Excess N (%) 4 (8%) 1 (4%) 3 (12%) 
   Previous excess N (%) 4 (8%) 2 (8%) 2 (8%) 
   Within limits N (%) 34 (71%) 18 (75%) 16 (67%) 
   None N (%) 6 (12%) 3 (12%) 3 (12%) 
Physical activity: Climb flight of stairs:- Nobs (Nmiss) 48 (0) 24 (0) 24 (0) 
   Unable N (%) 2 (4%) 0 (0%) 2 (8%) 
   With stopping N (%) 3 (6%) 2 (8%) 1 (4%) 
   Without stopping N (%) 43 (90%) 22 (92%) 21 (88%) 
 
 
 
Table 3: Comparison of Baseline Physical and Psychological Measurements of REx Trial 
Participants: Intervention group versus Control group. 
  
All 
(N = 48) 
Intervention 
(N = 24) 
Control 
(N = 24) 
Median steps per day Nobs (Nmiss) 46 (2) 23 (1) 23 (1) 
 Mean (SD) 7392 (3765) 7162 (3193) 7623 (3684) 
 Range 1152, 17422 1526, 17422 1152, 16472 
Sedentary N (%) 12 (26.1%) 8 (34.8%) 4 (17.4%) 
Slightly active N (%) 13 (28.3%) 5 (21.7%) 8 (34.8%) 
Moderately active N (%) 17 (37.0%) 8 (34.8%) 9 (39.1%) 
Very active N (%) 4 (8.7%) 2 (8.7%) 2 (8.7%) 
Waist circumference (cm) Nobs (Nmiss) 48 (0) 24 (0) 24 (0) 
 Mean (SD) 96.1 (9.4) 95.3 (11.1) 96.9 (7.6) 
Sit-to-stand test   (no. in 30 secs) Nobs (Nmiss) 48 (0) 24 (0) 24 (0) 
 Mean (SD) 11.3 (3.0) 11.3 (3.1) 11.4 (3.0) 
6 minute walking tests (m) Nobs (Nmiss) 48 (0) 24 (0) 24 (0) 
 Mean (SD) 436.2 (79.2) 435.7 (91.7) 436.7 (66.4) 
% of week spent active Nobs (Nmiss) 46 (2) 23 (1) 23 (1) 
 Mean (SD) 6.6 (2.8) 6.5 (2.8) 6.7 (2.9) 
% of week spent sedentary Nobs (Nmiss) 46 (2) 23 (1) 23 (1) 
 Mean (SD) 76.4 (12.1) 77.9 (7.3) 74.9 (15.6) 
EORTC-C30 Fatigue* Nobs (Nmiss) 46 (2) 23 (1) 23 (1) 
 Mean (SD) 23.9 (22.3) 27.5 (23.4) 20.3 (21.1) 
EORTC-C29 Embarrassment* Nobs (Nmiss) 47 (1) 24 (0) 23 (1) 
   Not at all N (%) 27 (57.4%) 14 (58.3%) 13 (56.5%) 
   A little N (%) 11 (23.4%) 4 (16.7%) 7 (30.4%) 
   Quite a bit N (%) 1 (2.1%) 1 (4.2%) 0 (0.0%) 
   Very much N (%) 8 (17.0%) 5 (20.8%) 3 (13.0%) 
PANAS     
Positive affect score Nobs (Nmiss) 47 (1) 24 (0) 23 (1) 
 Mean (SD) 33.6 (9.9) 35.0 (11.5) 32.1 (7.9) 
Negative affect score Nobs (Nmiss) 47 (1) 24 (0) 23 (1) 
 Mean (SD) 17.6 (7.0) 18.5 (7.4) 16.6 (6.5) 
BDI-II Nobs (Nmiss) 47 (1) 23 (1) 24 (0) 
 Mean (SD) 7.2 (6.6) 7.9 (7.3) 6.5 (6.1) 
Fact-C total score Nobs (Nmiss) 47 (1) 24 (0) 23 (1) 
 Mean (SD) 63.9 (10.9) 66.0 (8.6) 61.7 (12.8) 
* Selected results shown 
 
 
Table 4: Comparison of Changes in Physical and Psychological Measurements between Intervention and Control groups (Test 2 versus baseline Test 1). * Primary efficacy 
outcome   
** Adjusted for number of steps at baseline, age and gender. 
 
Intervention Control 
Group difference  
(Intervention – Control)  
N Mean (SD) Change from baseline (95% CI) N Mean (SD) Change from baseline (95% CI) Mean (95% CI) 
Median steps per day* 
Baseline 
17 
7779 (4045) 
-1105 (-2802, 593) 19 
7773 (3975)  
785 (-1195, 2765)** 
12 week 6675 (3100) 5920 (3152) -1853 (-3871, 164) 
Weight (kg) 
Baseline 
18 
76.7 (10.1) 
1.3 (-0.4, 3.0) 20 
77.3 (7.8)  
0.5 (-2.1, 3.1) 
12 week 78.0 (11.6) 78.2 (8.9) 0.8 (-1.2, 2.9) 
BMI 
Baseline 
18 
26.5 (3.0) 
0.3 (-0.2, 0.8) 20 
28.0 (3.4)  
0.2 (-0.6, 1.1) 
12 week 26.8 (3.4) 28.1 (3.3) 0.1 (-0.6, 0.8) 
Waist circumference (cm) 
Baseline 
18 
96.0 (9.7) 
-2.2 (-8.8, 4.4) 21 
97.7 (7.4)  
-4.4 (-11.3, 2.5) 
12 week 93.8 (17.9) 99.9 (7.7) 2.2 (-0.1, 4.5) 
Sit-to-stand test 
(no.completed in 30 secs) 
Baseline 
18 
11.5 (2.5) 
-0.4 (-2.2, 1.4) 22 
11.5 (3.0)  
-0.6 (-3.3, 2.2) 
12 week 11.1 (4.2) 11.7 (6.1) 0.1 (-2.1, 2.4) 
6 minute walking tests 
(m) 
Baseline 
18 
448.8 (64.9) 
13.7 (-50.1, 77.5) 22 
444.9 (59.2)  
68.5 (-27.2,164.2) 
12 week 462.5 (144.3) 390.1 (159.4) -54.8 (-130.4, 20.7) 
% of week spent active 
Baseline 
17 
6.6 (2.9) 
-0.8 (-2.1, 0.4) 19 
6.9 (3.1)  
0.3 (-1.7, 2.2) 
12 week 5.8 (2.6) 5.8 (2.3) -1.1 (-2.7, 0.5) 
% of week spent sedentary 
Baseline 
17 
76.0 (5.3) 
0.4 (-2.8, 3.6) 19 
74.8 (17.2)  
-2.7 (-13.2, 7.9) 
12 week 76.4 (7.6) 77.9 (7.6) 3.1 (-7.1,13.3) 
EORTC-C30 Fatigue 
Baseline 
17 
28.1 (23.6) 
0.7 (-13.7, 15.0) 20 
18.3 (19.8)  
-6.6 (-21.7, 8.5) 
12 week 28.8 (23.9) 25.6 (16.9) 7.2 ( 1.8,12.6) 
Positive affect score 
Baseline 
18 
36.2 (11.1) 
-3.7 (-10.2, 2.9) 20 
33.0 (8.0)  
-3.7 (-11.5, 4.2) 
12 week 32.5 (7.4) 33.0 (8.0) 0.0 (-4.7, 4.7) 
Negative affect score 
Baseline 
18 
18.9 (7.8) 
1.1 (-2.0, 4.2) 20 
16.1 (5.9)  
1.5 (-2.8, 5.8) 
12 week 20.0 (8.3) 15.7 (6.5) -0.4 (-3.7, 2.8) 
BDI-II 
Baseline 
15 
7.3 (5.9) 
0.7 (-1.7, 3.2) 22 
5.5 (4.4)  
-0.7 (-3.8, 2.5) 
12 week 8.1 (6.9) 7.0 (5.2) 1.4 (-0.7, 3.5) 
Fact-C total score 
Baseline 
18 
66.7 (8.9) 
-0.2 (-6.3, 6.0) 21 
60.5 (12.7)  
0.9 (-6.2, 8.0) 
12 week 66.5 (13.5) 59.4 (11.2) -1.1 (-5.1, 2.9) 
Table 5: Comparison of Clinico-Pathological Factors in Participants with Rectal Cancer recruited 
to the REx Trial: Intervention group versus Control group (patients who completed test 2 only). 
 
  All Participants 
N=40 
 
Intervention 
N=18 
Control 
N=22 
NACRT Started  N (%) 40 (100%) 18 (100%) 22 (100%) 
 Completed  Yes: No 39 (98%) 18 (100%) 21 (95%) 
Surgery Yes: No 36 (90%) 17 (94%) 19 (86%) 
 Elective * 35 (97%) 16 (94%) 19 (100%) 
 Laparoscopic/ lap assisted: 
lap-open : open 
6 (17%):  
4 (11%): 26 (72%) 
3 (18%):  
3(18%): 11 (65%) 
3 (16%):  
1 (5%): 15 (79%) 
Type of Surgery   N (%) Anterior Resection/ 
Hartmann’s procedure 
18 (50%) 10 (59%) 8 (42%) 
 APR 15 (42%) 6 (35%) 9 (47%) 
 Local Excision/ TAMIS 2 (6%) 0 2 (11%) 
 Palliative stoma formation 1 (3%) 1 (6%) 0 
Stoma formed Yes: no 33:3 17:0 16:3 
 Permanent: temporary 20: 13 8: 9 12:4 
Complications N (%) 24 (60%) 12 (67%) 12 (55%) 
Length of stay (days) Median (range) 10.5 (0.0 -38.2) 11.0 (6.0-37.0) 10 (0.0-38.2) 
TNM Staging (post-op)** T0 8 (23%) 4 (22%) 4 (18%) 
 T1 
T2 
T3 
3 (9%) 
7 (20%) 
16 (46%) 
1 (6%) 
1 (6%) 
10 (56%) 
2 (9%) 
6 (27%) 
9 (41%) 
 T4 1 (3%) 0 (0%) 1 (5%) 
 N0¶ 20 (61%) 10 (56%) 10 (45%) 
 N1 11 (33%) 5 (28%) 6 (27%) 
 N2 2 (6%%) 1 (6%) 1 (5%) 
No. of Lymph Nodes Median (range) 13.0 (0-43) 17 (4.0-43.0) 13 (0.0-27.) 
CRM clear¶ Yes: No 30: 3 15: 2 16: 1 
R0 Resection ** Yes: No 30: 5 13: 3 17: 2 
* n=1 obstruction, perforation 
** n=1 no pathology resected, defunctioning stoma only; percentage expressed out of total of 35 operations. 
¶ n=2 local excision where no nodal resection performed; percentage expressed out of a total of 33 operations. 
  
Figure 1: The REx Trial Consort Diagram. 
 
 
 
 
 
Total number of rectal cancers in GGC assessed 
for eligibility (n= 296) 
Analysis 
Follow-Up 
Recruitment rate: 62% 
 
Retention Rate: 83% 
 
Declined to participate (n=30) 
 Too busy/ too much going on (n=10) 
 Overwhelmed by diagnosis (n=5) 
 Agreed then DNA’d Test 1 (n=4) 
Too Unwell (n=4)  
Interfere with job (n=1) 
 Family/ friends advised against (n=1) 
 Unknown reason (n=5) 
  
 
 
Excluded (n=218) 
MDT decision not for NACRT  
Recruited (n= 48) 
Discontinued intervention (n=6) 
- emigrated prior to starting NACRT (N=1) 
- withdrew consent prior to starting CRT (n=1)  
- medical complications secondary to NACRT (n=3) 
- patient fatigue/ tiredness during NACRT (n=1) 
 
Eligibility rate: 26%  
 
Lost to follow-up (n=2) 
 - emergency surgery post-CRX (n=1) 
 - DNA Test 2 (n=1) 
 
Allocated to intervention (n= 24) 
  
 
Completed trial (n=18) 
 
Completed trial (n=22) 
 
Allocated to control group (n=24) 
 
 
 
 
Allocation 
Enrolment 
Eligible for trial (n=78) 
 Figure 2: Comparison of change in daily step count after intervention between Intervention 
and Control groups. 
 
 
